![IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg "IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
Company delivered strong earnings growth on slow Sales increase in the second quarter 2018, where earnings per share soared by 25000 % at $2.51 per share, Sales grew modestly by 1.95 % to $
53.08 billions from the same quarter a year ago.
In comparison to previous quarter EPS turn positive from $
-0.68 per share and Sales increased by 0.89 % from $52.61 billions.
Mckesson Corp said it's sales growth was driven by U.S. Healthcare direct distribution or services segment up 15.52% Pharmaceutical Solutions segment up 9.44% Medical-Surgical Solutions segment up 2.81%, while sales in Canada distribution or services segment fell -19.78%.
Earnings grew in following segments Pharmaceutical Solutions 16.77%. Earnings grew
887.5 % to $553 millions for the second quarter 2018, compare to income of $56 millions achieved a year before. Mckesson Corp also emphasized it's improving profit margins, where net margin rose to 1.04% in second quarter 2018, and operating margin edged up to 1.3%. Mckesson Corp cut it's annual earnings per share forecast by $
-2.24, now company expects eps from $9.96 to $10.46.
Mckesson Corp is expected to report next financial results on February 04, 2019.
